| Literature DB >> 36080247 |
Malik Saadullah1, Arshad Farid2, Asad Ali1, Muhammad Rashad1, Faiza Naseem3, Sheikh Abdur Rashid3, Shakira Ghazanfar4, Muhammad Yasin2, Nosheen Akhtar5, Mohammed S Almuhayawi6, Mohammed H Alruhaili6, Samy Selim7.
Abstract
Combretaceae, an immense family involving species (500) or genera (20), originates in tropical and subtropical regions. This family has evinced medicinal values such as anti-leishmanial, cytotoxic, antibacterial, antidiabetic, antiprotozoal, and antifungal properties. Conocarpus lancifolius (C. lancifolius) methanol extract (CLM) was prepared, then compound isolation performed by open column chromatography, and compound structure was determined by spectroscopic techniques (13C NMR, IR spectroscopy, 1H-NMR, mass spectrometry UV-visible, and 2D correlation techniques). Molecular docking studies of ligand were performed on transcriptional regulators 4EY7 and 2GV9 to observe possible interactions. Phytochemical screening revealed the presence of secondary metabolites including steroids, cardiac glycosides, saponins, anthraquinones, and flavonoids. The isolated compound was distinguished as lancifolamide (LFD). It showed cytotoxic activity against human breast cancer, murine lymphocytic leukemia, and normal cells, human embryonic kidney cells, and rat glioma cells with IC50 values of 0.72 µg/mL, 2.01 µg/mL, 1.55 µg/mL, and 2.40 µg/mL, respectively. Although no cytotoxic activity was noticed against human colon cancer and human lung cancer, LFD showed 24.04% inhibition against BChE and 60.30% inhibition against AChE and is therefore beneficial for Alzheimer's disease (AD). AChE and LFD interact mechanistically in a way that is optimum for neurodegenerative disorders, according to molecular docking studies. Methanol and dichloromethane extract of C. lancifolius and LFD shows antibacterial and antifungal activity against antibiotic resistance Bacillus subtilis, Streptococcus mutans, Brevibacillus laterosporus, Salmonella Typhi, Candida albicans, and Cryptococcus neoformans, respectively. LFD shows antiviral activity against HSV-1 with 26% inhibition IP. The outcomes of this study support the use of LFD for cognitive disorders and highlight its underlying mechanism, targeting AChE, DNA-POL, NF-KB, and TNF-α, etc., for the first time.Entities:
Keywords: Conocarpus lancifolius; anti-Alzheimer’s; anti-proliferative; anti-viral; antibiotic-resistant bacteria; combretaceae; cytotoxic; infection; lancifolamide
Mesh:
Substances:
Year: 2022 PMID: 36080247 PMCID: PMC9458197 DOI: 10.3390/molecules27175480
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1LFD isolation from C. lancifolius methanol extract.
Figure 2HPLC chromatogram and chemical structure of isolated compound of C. lancifolius “LFD”. HPLC data showed a single prominent peak of LFD.
Figure 3Chemical structure of lancifolamide.
Figure 4Mass fragmentation of LFD.
13C-NMR (125 MHz) or Chemical shift (1H-NMR 500MHz) spectral data of “LFD”.
| Carbon No. | Multiplicity | C13–NMR | Proton NMR | J. Value |
|---|---|---|---|---|
| C–1 | C | 109.50 | - | - |
| C–2 | C | 138.20 | - | - |
| C–3 | CH | 138.54 | 6.636 d | (J = 3.2, Hz, H-1) |
| C–4 | CH | 109.24 | 6.633 d | (J = 2.6, Hz, H-2) |
| C–5 | C | 108.20 | - | - |
| C–6 | CH | 109.40 | - | - |
| C–7 | C | 109.91 | - | |
| C–8 | C | 113.55 | - | - |
| C–9 | CH | 139.35 | - | - |
| C–10 | C | 139.92 | ||
| C–11 | C | 148.72 | - | - |
| C–12 | C | 105.55 | 6.857 d | (J = 3.1, 2.4 Hz, H-2) |
| C–13 | C | 110.22 | - | - |
| C–14 | C | 152.90 | - | - |
| C–15 | OCH3 | 54.45 | 3.347 s | (J = 4.2 Hz) |
| C–16 | OCH3 | 59.20 | 3.984 s | (J = 5.5 Hz) |
| C–17 | OCH3 | 60.55 | 4.580 s | (J = 4.4 Hz) |
| C–18 | OCH3 | 60.55 | 4.635 s | (J = 4.4 Hz) |
Docked ligands Surflex scores LFD, GLM and ACV in distinct protein binding site.
| Protein | Ligand | CScore | Crash Score | Polar Score | D Score | PMF Score | G Score | Chem Score | Amino Acid Interaction |
|---|---|---|---|---|---|---|---|---|---|
|
|
| 6.63 | −1.81 | 1.17 | −148.754 | −13.63 | −217.817 | −17.05 | G120, G121, G122, E202, H447, |
|
| 5.64 | −1.70 | 0.00 | −132.573 | −5.102 | −256.580 | −23.36 | G120, S125, Y133, | |
|
|
| 10.32 | −0.55 | 6.59 | −105.060 | −33.78 | −175.87 | −0.087 | Y101, E225, R176, M128, |
|
| 9.09 | −3.83 | 4.17 | −159.13 | −13.86 | −308 | −22.11 | R176, R222, M128, Y132 | |
|
|
| 6.72 | −1.18 | 0.10 | −129.044 | −51.80 | −255.476 | −20.96 | S106, E129, R132, R139, |
|
|
| 4.18 | −0.56 | 1.89 | −86.197 | −0.466 | −134.869 | −14.15 | Q118, A149 |
|
|
| 4.78 | −1.05 | 2.01 | −92.743 | 29.101 | −148.402 | −7.972 | H121, G122, E123, T166, |
|
|
| 3.86 | −4.33 | 2.73 | −169.628 | 114.664 | −300.937 | −22.57 | Y319, D321, S329 |
|
|
| 2.77 | −1.13 | 1.57 | −79.118 | −63.603 | −129.618 | −17.08 | Y59, Q149 |
; consensus scoring utilizes multiple scoring function types to rank ligands affinity, -score divulging inappropriate penetrating binding site, region, exhibiting complex (ligand–protein), hydrogen bonding, interior energies i.e., ligand to ligand, specifying Helmholtz free interaction energies for pairs protein to ligand atom (Mean Force Potential or PMF), for interactions such as Van der Waals or charge between ligand or protein, points for rotational entropy, lipophilic contact, hydrogen bonding with intercept term.
Figure 5Comparison of binding mode of tested compound LFD with the standard compounds Galantamine (GLM) and Acyclovir (ACV) bind to their respective targets. (A) LFD (magenta) and GLM (yellow) superposed in the same binding cavity of AChE enzyme. Best docking generated poses of selected ligands in AChE (B) GLM-AChE and (C) LFD-AChE. Superposition of LFD (magenta) and ACV (yellow). (D) Overall atomic model of LFD (E,F) ACV and LFD bonded to DNA-POL, respectively. Predicted bonding interactions of hydrogen illustrated in dashed lines (yellow).
Figure 6Top ranked docking conformations of our tested hit in selected proteins (A) LFD-BCL-XL, (B) LFD-BCL-2, (C) LFD-Caspases-3, (D) LFD-NF-kB, and (E) LFD-TNF-α. Predicted bonding interactions of hydrogen illustrated in dashed lines (yellow).
IC50 values of the C. lancifolius extracts (μg/mL). Mean ± SD (n = 3).
| Antioxidant Assays | CLD * | CLM ** | LFD *** | BHT | BHA | α-Tocopherol |
|---|---|---|---|---|---|---|
| DPPH | NA | 162.21 ± 4.56 | NA | 74.59 ± 1.98 | 16.19 ± 0.56 | 33.09 ± 0.68 |
| ABTS | NA | 69.16 ± 2.29 | 173.15 ± 6.73 | 18.35 ± 0.67 | 12.66 ± 0.47 | 19.35 ± 0.21 |
| β-Caroten | 139.12 ± 0.20 | NA | 140.91 ± 4.85 | 6.24 ± 0.39 | 5.06 ± 0.37 | 0.53 ± 0.73 |
* CLD: Dichloromethane extract of C. lancifolius. ** CLM: Methanol extract of C. lancifolius. *** LFD: Lancifolamide.
CUPRAC assay results. Mean ± SD (n = 3).
| Concentrations | 10 μg/mL | 25 μg/mL | 50 μg/mL | 100 μg/mL |
|---|---|---|---|---|
| CLD * | 0.13 ± 1.20 | 0.17 ± 0.42 | 0.22 ± 1.64 | 0.30 ± 2.35 |
| CLM ** | 0.13 ± 2.62 | 0.21 ± 1. 05 | 0.32 ± 0.65 | 0.49 ± 0.30 |
| Lancifolamide | 0.11 ± 2.54 | 0.19 ± 2.10 | 0.26 ± 1.85 | 0.41± 2.11 |
| BHA | 1.22 ± 0.35 | 1.60 ± 0.62 | 2.10 ± 0.55 | 2.39 ± 0.15 |
| BHT | 1.49 ± 1.15 | 1.78 ± 1.36 | 2.04 ± 0.70 | 2.42 ± 0.45 |
| α-Tocopherol | 0.29 ± 1.20 | 0.52 ± 0.90 | 0.68 ± 0.25 | 1.28 ± 1.10 |
* CLD: Dichloromethane extract of C. lancifolius. ** CLM: Methanol extract of C. lancifolius.
Cytotoxicity of pure compounds or crude extracts from C. lancifolius. Mean ± SD (n = 3).
| Crude Extracts/Pure Compounds | Cancer Cells | Normal Cells | ||||
|---|---|---|---|---|---|---|
| P-388 | Col-2 | MCF-7 | Lu-1 | ASK | Hek293 | |
| Dichloromethane | 8.15 ± 2.11 | 7.24 ± 2.50 | 1.19 ± 1.40 | 11.65 ± 1.95 | 9.04 ± 1.65 | 5.32 ± 0.54 |
| Methanol | 2.06 ± 2.01 | 8.14 ± 3.10 | 0.85 ± 2.66 | 7.64 ± 0.45 | 5.40 ± 0.30 | <4.00 |
| Compound (lancifolamide) | 2.01 ± 3.15 | NR * | 0.72 ± 3.92 | NR * | 2.40 ± 2.55 | 1.55 ± 1.02 |
| Ellipticine (Positive control) | 0.42 ± 0.03 | 0.53 ± 0.11 | 0.36 ± 0.92 | 0.22 ± 0.73 | 0.23 ± 0.70 | 0.57 ± 1.63 |
* NR: No response.
Assay of Anticholinesterase at 200µg/mL Mean ± SD (n = 3).
| Sample | Inhibition % against BChE | Inhibition % against AChE | IC50 Values in μg/mL |
|---|---|---|---|
| CLD * | 09.04 ± 0.11 | 69.10 ± 3.32 | 25.14 ± 2.62 |
| CLM ** | 5.73 ± 0.07 | 62.45 ± 2.53 | 29.55 ± 2.10 |
| Lancifolamide | 24.04 ± 1.93 | 60.30 ± 2.86 | 34.62 ± 1.40 |
| Galantamine | 76.25 ± 4.51 | 75.20 ± 2.78 | 13.20 ± 0.15 |
* CLD: Dichloromethane extract of C. lancifolius. ** CLM: Methanol extract of C. lancifolius.
Anti-HSV-1 extract activities along with lancifolamide compound secluded from C. lancifolius. Mean ± SD (n = 3).
| Compound | IC50 (mg/mL) | IP (%) |
|---|---|---|
| CLM | >100 | 17 ± 1.08 |
| CLD | >100 | 13 ± 0.86 |
| Lancifolamide | >100 | 26 ± 1.89 |
Antimicrobial and antifungal potential of extracts and lancifolamide.
|
|
|
|
|
|
|
|
|
| MIC | 0.275 | 0.275 | 0.275 | 7.8 | |
| MBC | 0.55 | 0.55 | 0.55 | 15.6 | ||
|
| MIC | 1.10 | 2.20 | 1.10 | 7.8 | |
| MBC | 2.20 | 4.40 | 2.20 | 15.6 | ||
|
| MIC | 0.137 | 0.275 | 0.137 | 3.9 | |
| MBC | 0.275 | 0.55 | 0.275 | 7.8 | ||
|
| MIC | 0.275 | 0.55 | 0.137 | 3.9 | |
| MBC | 0.55 | 1.10 | 0.275 | 7.8 | ||
|
|
| MIC | 0.55 | 2.20 | 0.55 | NT |
| MFC | 1.10 | 4.40 | 1.10 | NT | ||
|
| MIC | 0.275 | 0.275 | 0.275 | NT | |
| MFC | 0.55 | 0.55 | 0.55 | NT |